Alliances
As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline.
Arcus Biosciences and Genentech, a Roche company, are partnering on two clinical trials for colorectal and pancreatic cancer. They will evaluate Arcus’s AB928 in various combinations.
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
Recipharm, the contract development and manufacturing organisation has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.
Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut® Technology, have announced a partnership to commercialise the cell delivery potential of the polymer-based ‘bionic’ nanoparticles, which can carry a range of payloads directly to live cells.
Major learned societies initiate two-year strategic alliance
The deal allows Novoheart to merge its MyHeart Platform with Harvard’s tissue-engineered scale model of the heart ventricle and bioreactor technology.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces a strategic collaboration with Mammoth Biosciences, that will see the two companies develop new CRISPR tools to provide the next generation of engineered cell lines for the biopharmaceutical industry.
Verily, an Alphabet company, is partnering with Wake Forest Baptist Health and its Center for Healthcare Innovation to implement new solutions to improve the health and wellness of older adults and help them remain independent at home.
Almac Clinical Technologies has announced the launch of a standardized, operationally-proven integration between its Interactive Response Technology platform - IXRS® 3 and Exostar’s Identity and Access Management Platform.
PRESS RELEASES